MitoRx Therapeutics, an Oxford, England, UK-based biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, closed its seed financing.
The financial details of the deal were not disclosed.
Backers included the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors.
The company intends to use the funds for pre-clinical proof-of-concept platform development and explore research collaborations and partnerships.
The company also announces the appointment of Glyn Edwards MBE as Chair, who brings specialist industry experience developing therapeutics for Duchenne muscular dystrophy and progressing these to late-stage clinical trials.
Led by academic founder, and CSO, Prof Matt Whiteman of the University of Exeter, Dr Norman Law, Co-founder, and Dr. Jon Rees, CEO, MitoRx is a global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction. The preclinical research stage biotechnology company is developing its first-in-class, orally delivered, mitochondrial protective therapeutics targeting rare neuromuscular disorders, rare metabolic diseases, and neurodegenerative diseases.
FinSMEs
25/04/2022